medigraphic.com
Colegio de Medicina Interna de México.

2010, Number 5

<< Back Next >>

Med Int Mex 2010; 26 (5)

Septic shock and multiorganic dysfunction secondary to human influenza H1N1 virus

Carrillo-Esper R, Carrillo-Córdova CA, Carrillo-Córdova LD, Carrillo- Córdova JR

Language: Spanish
References: 38
Page: 501-507
PDF size: 312.35 Kb.


ABSTRACT

Background: H1N1 Influenza has several clinical patterns, from the autolimited flu-like symptomatology, to severe disease, characterized by acute respiratory distress syndrome, septic shock, and progressive multiorgan failure. The objective of this work is to make an evidence based proposal about the molecular and inflammation similarities, and clinical presentation between the severe form of the H1N1 influenza, severe sepsis and septic shock.
Clinic Case: Patient with pneumonia secondary to influenza virus AH1N1 infection which developed severe sepsis and septic shock. The patient was treated following the guidelines from the surviving sepsis campaing.
Conclusion: Sepsis and septic shock secondary to influenza A H1N1 infection has the same pathophysiological basis and clinical presentation than bacteria mediated severe sepsis and septic shock. This makes diagnostic and therapeutic approach similar in both diseases.



REFERENCES

  2. Solovyov A, Palacios G, Brieset T, Lipkin WI, Rabadan R. Cluster analysis of the origins of the new influenza A (H1N1) virus. Euro Surveill 2009;14:19244-19246.

  3. Rabadan R, Levine AJ, Krasnitz M. Non-random reassortment in human influenza A viruses. Influenza Other Respi Viruses 2008;2:9-22.

  4. Nelson MI, Viboud C, Simonsen L, et al. Multiple resentment events in the evolutionary history of H1N1 influenza A virus since 1918. Plos Pathog 2008; 29;4:e10000012.

  5. Zhou NN, Senne DA, Landgraf JS, et al. Genetic reassortment of avian, swine, and human A viruses in American pigs. J Virol 1999;73:8851-8856.

  6. World Health Organization (WHO). Pandemic (H1N1) 2009. Update 74. http://www.who.int/csr/don/2009_11_13/en/index. html

  7. Secretaría de Salud. Situación actual de la epidemia http:// portal.salud.gob.mx/sites/salud/descargas/pdf/influenza/ situacion_actual_epidemia_301009.pdf

  8. Gu J. H5N1 infection of the respiratory tract and beyond: A molecular pathology study. Lancet 370:1137-1145.

  9. Trammell RA, Toth LA. Genetic susceptibility and resistance to influenza infection and disease in humans and mice. Expert Rev Mol Diagn 2008;8:515-529.

  10. Baas T, Baskin CR, Diamond DL, Garcia-Sastre A, et al. Integrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics. J Virol 2006;80:10813-10828.

  11. Baskin CR, Brielefledt-Ohmann H, Tumpey TM, et al. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci USA 2009; 106: 3455-3460.

  12. Sládkova T, Kostolanský F. The role of cytokines in the immune response to influenza A virus infection. Acta Virol 2006;50:151- 62.

  13. Us D. Cytokine storm in avian influenza. Mikrobivol Bul 2008; 42: 365-380.

  14. Maines TR, Szretter KJ, Perrone L,Belser JA, Bright RA, Zeng H. Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Immunol Rev 2008;225:68-94.

  15. Sandbulte MR, Boon AC, Webby RJ, Riberdy JM. Analysis of cytokine secretion from human plasmacytoid dendritic cells infected with H5N1 or low-pathogenicity influenza viruses. Virology 2008;381:22-28.

  16. Zhou J, Law HK, Cheung CY, Nq IH, Peiris JS, Lau YL. Differential expression of chemokines and their receptors in adult and neonatal macrophages infected with human or avian influenza viruses. J Infect Dis 2006; 194;61-70.

  17. Chan MC, Chung CY, Chui WH, Tsao SW, Nicholls JM, Chan YO, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005;6:135-141.

  18. Mock CK, Lee DC, Cheung CY, Peiris M, Lau AS. Differential onset of apoptosis in influenza A virus H5N1- and H1N1-infected human blood macrophages. J Gen Virol 2007;88:1275- 1280.

  19. Wang G, Zhang J, Li W, et al. Apoptosis and proinflammatory cytokine responses of primary mouse microglia and astrocytes induced by human H1N1 and avian H5N1 influenza viruses. Cell Mol Immunol 2008;5:113-120.

  20. Lee N, Wong CK, Chan PK, Lun SW, Lui G, Wong B, et al. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin Infect Dis 2007; 45:723-731.

  21. Keller TT, van der Sluijs KF, de Kruift MD, Gerdes VE, Meijers JC, Florquin S, et al. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Cir Res 2006;11:1261-1269.

  22. Levi M. The coagulant response in sepsis. Clin Chest Med 2008;29:627-642.

  23. Horner C, Bouchon A, Bierhaus A, Nawroth PP, Martin E, Bardenheuer HJ, et al. Role of the innate immune response in sepsis. Anaesthesist 2004;53:10-28.

  24. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009;37:291-304.

  25. Tsujimoto H, Ono S, Efron PA, et al. Role of Toll-like receptors in the development of sepsis. Shock 2008;29:315-321.

  26. Annane D, Bellissant E, Cavaillon JM. Septic Shock. Lancet 2005;365:63-73.

  27. Marshall JC. Biomarkers of Sepsis. Curr Infect Dis Rep 2006;8:351-357.

  28. Kash JC, Tumpuy TM, Proll SC, Carter V, et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006;443:578-581.

  29. Fornek JL, Karth MJ, Katze MG. Use of functional genomics to understand influenza-host interactions. Adv Virus Res 2007;70:81-100.

  30. Henckaerts L, Nielsen KR, Steffensen R, Van Steen K, Mathieu C, Giulietti A. Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit. Crit Care Med 2009;37:192-201.

  31. Kumpf O, Schumann RR. Genetic influence on bloodstream infections and sepsis. Int J Antimicrob Agents 2008;32 Suppl 1:S44-S50.

  32. Liaw PC. Endogenous protein C activation in patinets with severe sepsis. Crit Care Med 2004;32:S214-S218.

  33. Cerchiara E, Tirindelli MC, Giannetti B, Dicuonzo G, Avvisati G. The numerous properties of the anticoagulant protein C. Clin Ter 2007;158:181-187.

  34. Bauer M, Brunkhorst F, Welte T, Gerlach H, Reinhart K. Sepsis. Update on pathophysiology, diagnostics and therapy. Anaesthesist 2006;55:835-845.

  35. Jennings LC, Monto AS, Chan PK, Suzcs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008;8:650-658.

  36. Oshitani H, Kamigaki T, Suzuki A. Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2008;14: 875-880.

  37. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006;43:199-205.

  38. Mann HJ, Short MA, Schlichting DE. Protein C in critical illness. Am J Health Syst Pharm 2009;66:1089-1096.




2020     |     www.medigraphic.com